TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15579792

Group type: EXPERIMENTAL
Intervention: l-arginine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: aerobic exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GH-releasing peptide (GHRP)-2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: somatostatin-induced rebound
Number of subjects: 16

Group type: COMPARATOR
Intervention: saline
Number of subjects: 16
Study: 10954887

Group type: EXPERIMENTAL
Intervention: Nucleoside analogue reverse transcriptase inhibitors
Number of subjects: 13045
Study: 9089057

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tricyclics (clomipramine and notriptyline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 0
Study: 8470979

Group type: EXPERIMENTAL
Intervention: 8 J of laser energy per application
Number of subjects: 89

Group type: COMPARATOR
Intervention: 4 J of laser energy per application
Number of subjects: 89
Study: 3544187

Group type: EXPERIMENTAL
Intervention: Low-dose antacid (Maalox 70, 280 mmol/day)
Number of subjects: 171

Group type: COMPARATOR
Intervention: H2-receptor antagonist cimetidine (Tagamet, 200 mg three times daily and 400 mg/day)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both groups (antacid and cimetidine)
Number of subjects: 171
Study: 31094083

Group type: EXPERIMENTAL
Intervention: CAP-B
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: CAPOX-B
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 414
Study: 30355453

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 days) plus best supportive care
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 507
Study: 27608894

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traditional resection
Number of subjects: 240
Study: 24478326

Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (subjects without ELS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (subjects with ELS)
Number of subjects: 0
Study: 23290327

Group type: EXPERIMENTAL
Intervention: Ziprasidone for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo for 6 weeks followed by ziprasidone for 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 120
Study: 20979731

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg three times a day for 5±2 days before PCI and a loading dose of 60 mg 30 minutes before PCI, continued for 4 weeks after procedure)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (similar treatment without trimetazidine)
Number of subjects: 101
Study: 18832293

Group type: EXPERIMENTAL
Intervention: Test formulation of tibolone (2.5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of tibolone (2.5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 24
Study: 16026526

Group type: EXPERIMENTAL
Intervention: Expert ratings of percussion sounds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnosis of ankylosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Periotest values (PTV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digital sound wave analysis
Number of subjects: 0
Study: 12934402

Group type: EXPERIMENTAL
Intervention: Nilestriol (Group A, n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (Group B, n = 20)
Number of subjects: 41
Study: 10493474

Group type: EXPERIMENTAL
Intervention: Collective feedback (whole sample)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group-only feedback (own professional group only)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mixed panels (managers and physicians)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Single-specialty panels (managers or physicians)
Number of subjects: 240
Study: 9199117

Group type: EXPERIMENTAL
Intervention: Offspring of hypertensive parents (both mothers and fathers)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no family history of hypertension)
Number of subjects: 85
Study: 1884611

Group type: COMPARATOR
Intervention: Normoventilation (pH 7.42, PCO2 41 torr)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Respiratory alkalosis (pH 7.59, PCO2 27 torr)
Number of subjects: 8
Study: 6298047

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (Embolization group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: One shot therapy (One shot group)
Number of subjects: 41
Study: 30628950

Group type: EXPERIMENTAL
Intervention: Hydrocortisone bolus (50 mg every 6 hours)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Hydrocortisone continuous infusion (200 mg/d)
Number of subjects: 58
Study: 28953070

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Workplace Dialogue Intervention (WDI)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: ACT + WDI
Number of subjects: 352

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 352
Study: 25872578

Group type: EXPERIMENTAL
Intervention: PALO (0.75 mg, i.v.) and DEX (9.9 mg, i.v.) on day 1
Number of subjects: 305

Group type: COMPARATOR
Intervention: PALO (0.75 mg, i.v.) and DEX (8 mg, i.v. or p.o.) on days 2-3
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: PALO plus DEX day 1
Number of subjects: 305

Group type: COMPARATOR
Intervention: PALO plus DEX days 1-3
Number of subjects: 305
Study: 24959952

Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron daily supplements for 16 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 80 mg elemental iron daily supplements for 16 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 22959886

Group type: EXPERIMENTAL
Intervention: Walnut diet (42.5 g of walnuts per 10.1 mJ 6 times per week)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fish diet (113 g of fatty fish per 10.1 mJ 2 times per week)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control diet (no nuts or fish)
Number of subjects: 25
Study: 19754498

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention in a geriatric unit (GI) including educational measures and specific actions in seven risk areas (orientation, sensory impairment, sleep, mobilization, hydration, nutrition, drug use).
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention in a geriatric unit (GI).
Number of subjects: 542

Group type: COMPARATOR
Intervention: Usual care in two internal medicine services (UC).
Number of subjects: 542
Study: 17446340

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (particulate concentration, 300 microg/m(3))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 15
Study: 15454616

Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 20

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 20
Study: 11442156

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam (MDL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol (APACHE II score > or = 20)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam (APACHE II score > or = 20)
Number of subjects: 20
Study: 9756554

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 6 g daily for 3 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 14
Study: 7836522

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI) using epididymal or testicular spermatozoa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional in-vitro fertilization (IVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICSI/MESA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 0
Study: 3401660

Group type: EXPERIMENTAL
Intervention: Cystoscopy plus urethral dilatation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cystoscopy alone
Number of subjects: 100
Study: 30942952

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (UNCOVER-3)
Number of subjects: 47
Study: 28688129

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg for 24 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg plus ribavirin for 16 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg plus ribavirin for 16 weeks (C‐CREST Part C)
Number of subjects: 73
Study: 26725391

Group type: EXPERIMENTAL
Intervention: Open lifestyle intervention for 22 weeks
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 109
Study: 23008337

Group type: EXPERIMENTAL
Intervention: Volunteers for treatment (n = 161)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Nonvolunteers for treatment (n = 443)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Unmatched volunteers
Number of subjects: 443

Group type: COMPARATOR
Intervention: Unmatched nonvolunteers
Number of subjects: 443
Study: 21496511

Group type: EXPERIMENTAL
Intervention: e‐DBT (multimedia e‐Learning course)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Manual (Linehan's Skills Training Manual for Borderline Personality Disorder)
Number of subjects: 132

Group type: COMPARATOR
Intervention: e‐Control (placebo control e‐Learning course)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: e‐DBT
Number of subjects: 132
Study: 18451321

Group type: EXPERIMENTAL
Intervention: 80 mmol/day of oral sodium supplements (normal sodium intake)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Matched placebo (low sodium intake)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 220
Study: 16585019

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6 mg) on day 4 or 8 of each cycle
Number of subjects: 41
Study: 12927004

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 4611

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 4611
Study: 11044005

Group type: EXPERIMENTAL
Intervention: Oral predictive thermometer
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: IRED tympanic thermometer
Number of subjects: 500

Group type: COMPARATOR
Intervention: Oral glass mercury thermometer
Number of subjects: 500
Study: 8867395

Group type: EXPERIMENTAL
Intervention: HRT (hormonal replacement therapy)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-HRT (no hormone regimen)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-HRT
Number of subjects: 93
Study: 1611373

Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for recurrent wheezy chest
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Control condition (no standard setting)
Number of subjects: 9000
Study: 6734056

Group type: EXPERIMENTAL
Intervention: 15-mg quazepam tablet at night just before sleep
Number of subjects: 12

Group type: COMPARATOR
Intervention: 15-mg quazepam tablet in the morning after a night's sleep
Number of subjects: 12
Study: 3026039

Group type: EXPERIMENTAL
Intervention: Ca-gluconate (1.58 g Ca)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ossopan (osseino-mineral complex, 1.58 g Ca)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Comparison of 24-hour urine excretion
Number of subjects: 13
Study: 31965527

Group type: EXPERIMENTAL
Intervention: Black physician
Number of subjects: 238

Group type: COMPARATOR
Intervention: White physician
Number of subjects: 238
Study: 29055155

Group type: EXPERIMENTAL
Intervention: apremilast 30 mg bid
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 26645588

Group type: EXPERIMENTAL
Intervention: Mipomersen (50-400 mg, administered subcutaneously or via a 2-h intravenous infusion)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Mipomersen (200 mg IV)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg IV)
Number of subjects: 87
Study: 24255061

Group type: EXPERIMENTAL
Intervention: evolocumab+SOC
Number of subjects: 1104

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 1104
Study: 22894911

Group type: EXPERIMENTAL
Intervention: Rapeseed oil diet enriched with α-linolenic acid (ALA) (3.5 g/d)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Olive oil diet rich in MUFA but low in ALA
Number of subjects: 81
Study: 20838622

Group type: EXPERIMENTAL
Intervention: High-dose folic acid (0.8 mg/d), vitamin B12 (0.5 mg/d), and vitamin B6 (20 mg/d) for 24 months
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: High-dose B vitamins
Number of subjects: 271
Study: 18929098

Group type: EXPERIMENTAL
Intervention: Predictive models for glaucoma development
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive models for glaucoma progression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current models for assessing risk of glaucoma development
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limitations of predictive models
Number of subjects: 0
Study: 16024212

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) group
Number of subjects: 120

Group type: COMPARATOR
Intervention: No Decision Aid (NDA) group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 12842237

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 to 20 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual therapy (Control)
Number of subjects: 29
Study: 10375147

Group type: EXPERIMENTAL
Intervention: Representative payeeship
Number of subjects: 54
Study: 8876922

Group type: EXPERIMENTAL
Intervention: In-person progress reports from perioperative nurses
Number of subjects: 200

Group type: COMPARATOR
Intervention: Attention protocol (checklist explaining hospital routines, waiting room procedures)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Telephone progress reports
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard perioperative care (control group)
Number of subjects: 200
Study: 2060564

Group type: EXPERIMENTAL
Intervention: Caffeine 12 mg.kg‐1.day‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine 4.2 mg.kg‐1.day‐1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6140018

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30368796

Group type: EXPERIMENTAL
Intervention: 15 g of honey
Number of subjects: 30

Group type: COMPARATOR
Intervention: 15 g of marmalade (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Honey vs Glucose solution
Number of subjects: 30
Study: 30390827

Group type: EXPERIMENTAL
Intervention: Blind condition (ride on feel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Associative condition (focusing on skills for efficient cycling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dissociative condition (focusing concentration elsewhere)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full feedback condition (pace regulated via observation)
Number of subjects: 0
Study: 27184093

Group type: EXPERIMENTAL
Intervention: Negative bronchial genomic classifier result (low risk)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Positive bronchial genomic classifier result (intermediate risk)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Classifier results reported for patients with benign disease
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Classifier results reported for patients with malignant disease
Number of subjects: 36
Study: 24438173

Group type: EXPERIMENTAL
Intervention: 23 °C trial
Number of subjects: 10

Group type: COMPARATOR
Intervention: 38 °C trial
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both trials
Number of subjects: 10
Study: 22430269

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) integrated with standard oncology care
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard oncology care alone
Number of subjects: 151
Study: 20075644

Group type: EXPERIMENTAL
Intervention: 16-mg ER hydromorphone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 32-mg ER hydromorphone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 64-mg ER hydromorphone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8-mg IR hydromorphone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8-mg ER hydromorphone (milled)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18940481

Group type: EXPERIMENTAL
Intervention: Open-reduction and rigid internal fixation (ORIF)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Maxillomandibular fixation (MMF)
Number of subjects: 142
Study: 16091635

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 11685061

Group type: EXPERIMENTAL
Intervention: Ocular blood flow tonometer (OBF)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Tonopen
Number of subjects: 69

Group type: COMPARATOR
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 69
Study: 9716159

Group type: EXPERIMENTAL
Intervention: 25 mg rHDL/kg body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg rHDL/kg body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro rHDL
Number of subjects: 0
Study: 7990026

Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allograft (DFDBA) with barrier material
Number of subjects: 36

Group type: COMPARATOR
Intervention: No DFDBA (control)
Number of subjects: 36
Study: 2917591

Group type: EXPERIMENTAL
Intervention: Diltiazem 30 mg t.d.s. for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg after diltiazem pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 956002

Group type: EXPERIMENTAL
Intervention: Slow speaking rate (90 words/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal speaking rate (140 words/min)
Number of subjects: 24
Study: 31033774

Group type: EXPERIMENTAL
Intervention: Single-leg knee-extensor (KE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single-leg cycle ergometry (CE)
Number of subjects: 10
Study: 29535047

Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype-guided opioid prescribing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional pain management strategy
Number of subjects: 0
Study: 27548212

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BTJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20
Study: 24724616

Group type: EXPERIMENTAL
Intervention: rs1800497 variant in women
Number of subjects: 25000

Group type: COMPARATOR
Intervention: rs1800497 variant in men
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: rs6275 variant in women
Number of subjects: 25000

Group type: COMPARATOR
Intervention: rs6275 variant in men
Number of subjects: 25000
Study: 22012257

Group type: EXPERIMENTAL
Intervention: CYP2C19*2 genotype
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ALDH3A1*2 genotype
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: GSTA1*B genotype
Number of subjects: 68
Study: 19382614

Group type: EXPERIMENTAL
Intervention: Raloxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New SERMs (ospemifen, lasofoxifen, bazedoxifen, arzoxifen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SERM with parathormone or SERM with bisphosphonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: SERM with conventional hormonal replacement therapy
Number of subjects: 0
Study: 17536191

Group type: EXPERIMENTAL
Intervention: High total dairy product consumption (4th quartile)
Number of subjects: 3627

Group type: EXPERIMENTAL
Intervention: Increasing calcium intake
Number of subjects: 3627
Study: 15464683

Group type: EXPERIMENTAL
Intervention: Ventricular Response Pacing (VRP) algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 11430602

Group type: EXPERIMENTAL
Intervention: 1-day training course and resource pack for head and neck cancer nurses
Number of subjects: 8
Study: 9251066

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg daily) with entacapone (200 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo with entacapone (200 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 13

Group type: COMPARATOR
Intervention: Selegiline and Placebo
Number of subjects: 13
Study: 8480959

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 to 80 mg/d)
Number of subjects: 3390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3390
Study: 3816087

Group type: EXPERIMENTAL
Intervention: Standing up
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Head-up tilt (70 degrees)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Active standing
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Postural change
Number of subjects: 2
Study: 29382673

Group type: EXPERIMENTAL
Intervention: Internet-based care programme
Number of subjects: 433

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 433
Study: 25710083

Group type: EXPERIMENTAL
Intervention: NRP Cart
Number of subjects: 55

Group type: COMPARATOR
Intervention: Generic storage drawer
Number of subjects: 55
Study: 25063211

Group type: EXPERIMENTAL
Intervention: FBP0.9 (0.9 mGy, 120 kV)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: FBP0.5 (0.5 mGy, 100 kV)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: FBP0.2 (0.2 mGy, 80 kV)
Number of subjects: 29

Group type: COMPARATOR
Intervention: SD-FBP (standard dose, 120 kV, 6 ± 1 mGy)
Number of subjects: 29
Study: 23728281

Group type: EXPERIMENTAL
Intervention: Within-team debriefing
Number of subjects: 120

Group type: COMPARATOR
Intervention: Instructor-led debriefing
Number of subjects: 120